Highly Upregulated Expression of CD36 and MSR1 in Circulating Monocytes of Patients with Acute Coronary Syndromes
Authors:
Open Access
- 5 July 2012
- journal article
- research article
- Published by Springer Nature in The Protein Journal
- Vol. 31 (6) , 511-518
Abstract
Acute Coronary Syndromes (ACS) are a group of disorders caused by the significant reduction of circulation in coronary arteries. The most common reason of the dysfunction is a blood clot formed in place of plaque rupture. The role of scavenger receptors in development and progression of atherosclerosis has been confirmed in many animal experiments, however the knowledge about contribution of the receptors in the development of ACS symptoms in humans still remains insufficient. The aim of this work was to define the expression of two scavenger receptors: CD36 and MSR1 in monocytes of patients with ACS after the onset of symptoms and after the 6 months of treatment. The analysis of CD36 and MSR1 expression was carried out with the use of real-time PCR and flow cytometry. Analyses of lipid and glucose concentration in blood and the level of inflammatory markers in plasma were performed additionally for all ACS patients. All data obtained during the research were analyzed using statistical tests, such as Mann Whitney test, Wilcoxon test, or correlation. In all patients with symptoms of ACS the amount of CD36 and MSR1 mRNA in circulating monocytes, as well as the density of both receptors on the cells surface was significantly higher. Re-analysis of subjects after 6 months of treatment, showed a significant decrease in the CD36 and MSR1 expression in all patients who received atorvastatin. The results of presented studies demonstrate that both investigated receptors are involved in the development and/or progression of ACS.Keywords
This publication has 40 references indexed in Scilit:
- Atorvastatin Downregulates Monocyte CD36 Expression, Nuclear NFκB and TNFα Levels in Type 2 DiabetesJournal of Atherosclerosis and Thrombosis, 2010
- Immune and Inflammatory Mechanisms of AtherosclerosisAnnual Review of Immunology, 2009
- CD36: Implications in cardiovascular diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary SyndromesJACC, 2005
- Statin effects beyond lipid lowering—are they clinically relevant?European Heart Journal, 2003
- Atherosclerotic Lesions Grow Through Recruitment and Proliferation of Circulating Monocytes in a Murine ModelThe American Journal of Pathology, 2002
- CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolismJournal of Clinical Investigation, 2001
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993